Emerging Multiple Myeloma Data and Future Outlook From ASCO 2025

EP: 1.Treatment Approaches and Goals: Transplant-Eligible vs. Transplant-Ineligible Patients

EP: 2.The Role of ASCT in Frontline Myeloma: Comparative Risks and Benefits with Other Standard Treatment Approaches

EP: 3.Evaluating First-Line Treatment Options: Quadruplet vs Triplet Regimens and NCCN Guidelines

EP: 4.The Role of MRD Status in Post-ASCT Treatment Decisions and Clinical Integration

EP: 5.Tailoring Maintenance Therapy by Patient Risk: Lenalidomide Alone vs Combination Approaches

EP: 6.Balancing Timing of ASCT: Insights on Delayed Transplantation and Long-Term Treatment Outcomes

EP: 7.Managing Early Relapse in Transplant-Eligible MM and the Influence of Clonal Evolution

EP: 8.Advancing Frontline Therapy in Transplant-Eligible Myeloma and Emerging Trends in Smoldering Myeloma Management

EP: 9.Evolving Treatment Strategies in Transplant-Ineligible NDMM: Expert Insights From CEPHEUS, IMROZ and BENEFIT

EP: 10.Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics

EP: 11.Balancing Deeper Response and MRD Negativity With Toxicity Risks in Clinical Decision-Making

EP: 12.Therapy Selection and Management Strategies for Transplant-Ineligible Older Patients

EP: 13.Expert Perspectives on Balancing QOL, Convenience, and Depth of Treatment Response

EP: 14.Key Takeaways From CEPHEUS: Subgroup Analysis

EP: 15.PERSEUS and ADVANCE Updates: Evolving Approaches to MRD-Driven Myeloma Care

EP: 16.Advancing First-Line Therapy for Multiple Myeloma: Updates From IsKia and IMROZ Trials

Now Viewing

EP: 17.Emerging Multiple Myeloma Data and Future Outlook From ASCO 2025

Upcoming ASCO presentations include significant developments in CAR T-cell therapy, with long-term follow-up of ide-cel showing potential plateau curves at 5-year follow-up, suggesting possible cure in heavily pretreated patients. The MIDAS trial represents the first study using , minimal residual disease (MRD)at 10–5 as an escalation versus de-escalation end point, though early treatment reduction may be premature given the complexity of high-risk disease biology and response patterns.

Tri-specific antibodies represent the next evolution beyond bispecific therapies, combining CD3, CD38, and potentially other targets for enhanced antimyeloma activity. Early response rates appear promising, though detailed safety profiles and patient selection criteria require further evaluation. MRD monitoring is becoming increasingly integrated into clinical practice and trial design, emphasizing the need for standardized testing and interpretation protocols.

Economic considerations and pharmacoeconomic value are becoming increasingly important in treatment selection, particularly regarding the potential for treatment discontinuation in patients achieving sustained MRD negativity. The possibility of maintenance-free intervals for patients with deep, sustained responses could significantly impact cost-effectiveness and quality of life. Future directions emphasize personalized medicine approaches, with treatment intensity guided by risk stratification, MRD monitoring, and individual patient factors to optimize both clinical outcomes and health care resource utilization.